Skip to content

Colchicine effects on Major Adverse Cardiac Events in patients who underwent PCI

Evaluation the outcomes of major adverse cardiac events after six-month colchicine consumption in the patients with ST-elevation myocardial infarction that underwent primary percutaneous coronary intervention.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230801059005N1
Enrollment
204
Registered
2023-08-21
Start date
2023-09-23
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-elevation myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: In the intervention group, in addition to standard treatment for myocardial infarction with ST-segment elevation, colchicine is administered orally (tablet) at a da

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who had experienced ST-elevation myocardial infarction (STEMI) In angiography of patients, in at least one of the epicardial arteries larger than or equal to two and a half millimeters, there should be a stenosis equal to or greater than fifty percent, which has been managed through percutaneous coronary intervention and medical therapy. patients were undergoing percutaneous coronary intervention (PCI).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac events. Timepoint: at the beginning- 3 month- 6month. Method of measurement: questionnaire- angiography.

Secondary

MeasureTime frame
Myocardial infarctions, chest pain, resuscitated cardiac arrests, cardiovascular-related deaths, and strokes. Timepoint: at the beginning- 3 month- 6 month. Method of measurement: medical records- questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Safari

Shiraz University of Medical Sciences

Dr.safari.interventionist@gmail.com+98 71 3233 4196

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026